Regeneron Pharmaceuticals (REGN)
$344.87 6.48 (1.91%)
17:42 EST REGN Stock Quote Delayed 15 Minutes
Previous Close $344.87
Market Cap 36.54B
PE Ratio 27.95
Volume (Avg. Vol.) 912,200
Day's Range 338.71 - 349.86
52-Week Range 271.37 - 442.00
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
Thursday's big stock charts detail the hopes for 3 stocks trying to recover from multi-year lows.
Regeneron Pharmaceuticals (REGN) earnings for the biotechnology company's third quarter of 2019 have REGN stock soaring on Tuesday.
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Of the undervalued stocks that Goldman Sachs recently thrust into the spotlight, these three are the most promising stocks to buy. Here's what you need to know about each.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
While some companies are doing a good job closing their CEO-Worker wage gaps, these seven companies are not.
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
No company can guarantee its future, but here are some that are well-positioned to take advantage of current trends.
It might seem like an odd pairing, but WING and REGN stock have similar leadership qualities off and on the price chart.
The best stocks to buy at the bottom of a bear market are those you can see growing over the next three to five years.
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Regeneron Pharmaceuticals, Inc. (REGN), where a total volume of 6,805 contracts has been traded thus far today, a contract volume which is representative of approximately 680,500 underlying shares (given that every 1 contract represents 100 underlying shares)..
From Market News Video
From Analyst Ratings
Yesterday, the EVP Research and Development of Regeneron (REGN – Research Report), Neil Stahl, sold shares of REGN for $2.49M. In addition to Neil Stahl, one other REGN executive reported Sell trades in the last month. See today’s analyst top recommended stocks >> Based on Regeneron’s latest earnings report for the quarter ending September 30,
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!